Shalapour Shabnam, Lin Xue-Jia, Bastian Ingmar N, Brain John, Burt Alastair D, Aksenov Alexander A, Vrbanac Alison F, Li Weihua, Perkins Andres, Matsutani Takaji, Zhong Zhenyu, Dhar Debanjan, Navas-Molina Jose A, Xu Jun, Loomba Rohit, Downes Michael, Yu Ruth T, Evans Ronald M, Dorrestein Pieter C, Knight Rob, Benner Christopher, Anstee Quentin M, Karin Michael
Laboratory of Gene Regulation and Signal Transduction, Department of Pharmacology, School of Medicine, University of California San Diego (UCSD), 9500 Gilman Drive, La Jolla, California 92093, USA.
Biomedical Translational Research Institute and The First Affiliated Hospital, Jinan University, Guangzhou 510632, China.
Nature. 2017 Nov 16;551(7680):340-345. doi: 10.1038/nature24302. Epub 2017 Nov 8.
The role of adaptive immunity in early cancer development is controversial. Here we show that chronic inflammation and fibrosis in humans and mice with non-alcoholic fatty liver disease is accompanied by accumulation of liver-resident immunoglobulin-A-producing (IgA) cells. These cells also express programmed death ligand 1 (PD-L1) and interleukin-10, and directly suppress liver cytotoxic CD8 T lymphocytes, which prevent emergence of hepatocellular carcinoma and express a limited repertoire of T-cell receptors against tumour-associated antigens. Whereas CD8 T-cell ablation accelerates hepatocellular carcinoma, genetic or pharmacological interference with IgA cell generation attenuates liver carcinogenesis and induces cytotoxic T-lymphocyte-mediated regression of established hepatocellular carcinoma. These findings establish the importance of inflammation-induced suppression of cytotoxic CD8 T-lymphocyte activation as a tumour-promoting mechanism.
Nature. 2017-11-16
J Immunother Cancer. 2022-5
Cell Mol Immunol. 2025-8-6
Nat Rev Cancer. 2025-8-4
JHEP Rep. 2025-4-2
mSystems. 2017-3-7
J Clin Invest. 2016-12-1
Curr Protoc Bioinformatics. 2016-9-7
Nat Methods. 2016-8-30
Cell Host Microbe. 2015-12-9